Drug
Satralizumab clinical trials
Also written SA237 and RG6168.
- studies test it
- 14
- open now
- 2
- in phase 3
- 9
- first study started
- 2014
Keep track of what changes. Save the satralizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 2
- 2
- Phase 3
- 9
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 3
Hoffmann-La Roche (11) · International University of Health and Welfare (1) · Massachusetts General Hospital (1) · University of Florida (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses satralizumab is read from its arms, and is right about nine times in ten.
Testing it · 14
- A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)RecruitingPhase 3Hoffmann-La RocheNCT05199688Written as Satralizumab
- Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSDRecruitingPhase 4Massachusetts General HospitalNCT07010302Written as Satralizumab
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated DiseaseActive, not recruitingPhase 3Hoffmann-La RocheNCT05271409Written as Satralizumab
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisActive, not recruitingPhase 3Hoffmann-La RocheNCT05503264Written as Satralizumab
- A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)Active, not recruitingPhase 2Hoffmann-La RocheNCT06450639Written as Satralizumab
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye DiseaseCompletedPhase 3Hoffmann-La RocheNCT06106828Written as Satralizumab
- Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye DiseaseCompletedPhase 3Hoffmann-La RocheNCT05987423Written as Satralizumab
- Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)CompletedPhase 2International University of Health and WelfareNCT05679570Written as Satralizumab (Genetical Recombination)
- Satralizumab in Aneurysmal Subarachnoid HemorrhageWithdrawnEarly Phase 1University of FloridaNCT05727657Written as Satralizumab
- A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia GravisTerminatedPhase 3Hoffmann-La RocheNCT04963270Written as Satralizumab
- A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An InterventionTerminatedPhase 4Hoffmann-La RocheNCT05269667Written as Satralizumab 120 mg
- A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)CompletedPhase 3Hoffmann-La RocheNCT04660539Written as satralizumab
- Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)CompletedPhase 3Hoffmann-La RocheNCT02028884Written as Satralizumab
- Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)CompletedPhase 3Hoffmann-La RocheNCT02073279Written as Satralizumab
Codes
What other systems call satralizumab · ClinicalTrials.gg INT001230
- MeSH (NLM) C000655944satralizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) YB18NF020MSATRALIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2391541One source FDA
- Wikidata Q58218746satralizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152307SatralizumabOne source FDA
- DrugBank DB15762One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000655944 | satralizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | YB18NF020M | SATRALIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2391541 | — | One source FDA |
| Wikidata | Q58218746 | satralizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152307 | Satralizumab | One source FDA |
| DrugBank | DB15762 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.